Form 4 for MNPR Monopar Therapeutics
Accepted 2022-01-04 00:00:00 ET · period of report 2021-12-31 · accession 0001654954-22-000124 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-01-04 | 2021-12-31 | MNPR | Robinson Chandler | CEO, Dir | M - OptEx | — | +3,941 | 30.7K | +15% | — |
| D | 2022-01-04 | 2021-12-31 | MNPR | Robinson Chandler | CEO, Dir | F - Tax | $3.21 | -1,364 | 29.3K | -4% | -$4,378 |
| D | 2022-01-04 | 2021-12-31 | MNPR | Robinson Chandler | CEO, Dir | M - OptEx | $0.00 | -3,941 | 47.3K | -8% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-12-31 | M | A | 3,941 | — | 30,699.80 | D | — | — | (F1) Represents shares acquired on vesting and settlement of restricted stock units. |
| 2 | Common | Common Stock | 2021-12-31 | F | D | 1,364 | $3.21 | 29,335.80 | D | — | — | |
| 3 | Derivative | Restricted Stock Units | 2021-12-31 | M | D | 3,941 | $0.00 | 47,295 | D | — · — to — | 3,941 Common Stock | (F1) Represents shares acquired on vesting and settlement of restricted stock units. (F4) On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. |